<DOC>
	<DOC>NCT02754219</DOC>
	<brief_summary>The objective of the study is to compare the pharmacokinetics profiles and safety of Evogliptin in patients wit hepatic dysfunction versus healthy volunteers after single oral dose of Evogliptin</brief_summary>
	<brief_title>Pharmacokinetics and Safety of Evogliptin in Subjects With Hepatic Dysfunction</brief_title>
	<detailed_description>When the future evogliptin be administered to liver dysfunction patients, to investgate whether dose adjustment is necessary.</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>&lt;Hepatic Dysfunction&gt; At least 6 months with chronic liver disease (Regardless of cause hepatic dysfunction) ChildPugh A or B &lt;Healthy Control&gt; Subject has the following conditions: age ± 5 years, BMI ± 20%, same sex of each matched hepatic dysfunction subject &lt;Hepatic Dysfunction&gt; ChildPugh C History of Liver transplant &lt;Healthy Control&gt; History of chronic liver disorders Pregnant or lactating women</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Diabetes Mellitus, Type II</keyword>
</DOC>